Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).
Atomo Diagnostics Ltd. has reported significant growth in its HIV Self-Test business in Australia, securing a $440k order for tests funded by the Australian government, and is expanding into New Zealand with a commercial launch in April. The company also renegotiated a long-term agreement with Newfoundland Diagnostics in Europe, aiming to leverage established retail channels for its products. Additionally, Atomo has received a $2.44 million government grant to develop a novel syphilis test, partnering with the Burnet Institute and IDE Group to expand its market reach with a test that can be used by both clinicians and consumers.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. operates in the medical diagnostics industry, primarily focusing on the development and supply of rapid diagnostic tests. The company is known for its HIV Self-Test business, targeting developed markets, and is expanding its portfolio with the development of a new syphilis test.
YTD Price Performance: -5.00%
Average Trading Volume: 215,165
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$12.14M
Learn more about AT1 stock on TipRanks’ Stock Analysis page.
